IL55774A
(en)
*
|
1977-10-28 |
1982-04-30 |
Sparamedica Ag |
Pharmaceutical compositions containing urea derivatives,certain such novel derivatives and their manufacture
|
MC1220A1
(fr)
*
|
1977-10-28 |
1979-07-20 |
Hoffmann La Roche |
Nouveaux derives d'imidazolidine
|
FI801184A
(fi)
*
|
1979-04-24 |
1980-10-25 |
Hoffmann La Roche |
Foerfarande foer framstaellning av imidazolidinderivat
|
US4760053A
(en)
*
|
1984-08-02 |
1988-07-26 |
Fernand Labrie |
Combination therapy for selected sex steroid dependent cancers
|
ATE75947T1
(de)
*
|
1984-08-02 |
1992-05-15 |
Labrie Fernand |
Pharmazeutische zusammensetzung fuer die kombinationstherapie von hormonabhaengigem krebs.
|
US4775660A
(en)
*
|
1984-08-02 |
1988-10-04 |
Fernand Labrie |
Treatment of breast cancer by combination therapy
|
US4666885A
(en)
*
|
1985-02-08 |
1987-05-19 |
Fernand Labrie |
Combination therapy for treatment of female breast cancer
|
IT1214735B
(it)
*
|
1986-11-04 |
1990-01-18 |
Roussel Maestretti Spa |
Impiego di 1-(3'-trifluorometil 4'nitrofenil) 4,4-dimetilimidazolin2,5-dione per il trattamento di cancri ormonodipendenti diverso da quello della prostata
|
US5084472A
(en)
*
|
1986-11-04 |
1992-01-28 |
Roussel |
Application of 1-(3'-trifluoromethyl-4'-nitrophenyl)-4,4'-dimethylimidazoline 2,5-dione in the treatment of hormone-dependent cancers other than that of the prostate
|
FR2619381B1
(fr)
*
|
1987-08-13 |
1989-12-08 |
Roussel Uclaf |
Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation
|
US4895715A
(en)
*
|
1988-04-14 |
1990-01-23 |
Schering Corporation |
Method of treating gynecomastia
|
FR2656302B1
(fr)
*
|
1989-12-22 |
1992-05-07 |
Roussel Uclaf |
Nouveau procede de preparation de l'anandron et derives de l'anandron.
|
FR2693461B1
(fr)
*
|
1992-07-08 |
1994-09-02 |
Roussel Uclaf |
Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
|
US5411981A
(en)
*
|
1991-01-09 |
1995-05-02 |
Roussel Uclaf |
Phenylimidazolidines having antiandrogenic activity
|
USRE35956E
(en)
*
|
1991-01-09 |
1998-11-10 |
Roussel Uclaf |
Phenylimidazolidines having antiandrogenic activity
|
FR2671348B1
(fr)
*
|
1991-01-09 |
1993-03-26 |
Roussel Uclaf |
Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
|
FR2706456B1
(fr)
*
|
1993-06-18 |
1996-06-28 |
Rhone Poulenc Agrochimie |
Dérivés optiquement actifs de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
|
FR2685328B1
(fr)
*
|
1991-12-20 |
1995-12-01 |
Rhone Poulenc Agrochimie |
Derives de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
|
US6002016A
(en)
*
|
1991-12-20 |
1999-12-14 |
Rhone-Poulenc Agrochimie |
Fungicidal 2-imidazolin-5-ones and 2-imidazoline-5-thiones
|
FR2694290B1
(fr)
*
|
1992-07-08 |
1994-09-02 |
Roussel Uclaf |
Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
|
US6008370A
(en)
*
|
1992-11-25 |
1999-12-28 |
Rhone-Poulenc Agrochimie |
Fungicidal-2-alkoxy/haloalkoxy-1-(mono- or disubstituted)amino-4,4-disubstituted-2-imidazolin-5-ones
|
FR2715402B1
(fr)
*
|
1994-01-05 |
1996-10-04 |
Roussel Uclaf |
Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
|
FR2724169B1
(fr)
*
|
1994-09-06 |
1997-01-03 |
Roussel Uclaf |
Nouvelles phenylimidazolidines eventuellement substituees, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
|
TW521073B
(en)
*
|
1994-01-05 |
2003-02-21 |
Hoechst Marion Roussel Inc |
New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
|
FR2725206B1
(fr)
*
|
1994-09-29 |
1996-12-06 |
Roussel Uclaf |
Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
|
US5656651A
(en)
*
|
1995-06-16 |
1997-08-12 |
Biophysica Inc. |
Androgenic directed compositions
|
US6566372B1
(en)
|
1999-08-27 |
2003-05-20 |
Ligand Pharmaceuticals Incorporated |
Bicyclic androgen and progesterone receptor modulator compounds and methods
|
IL152719A0
(en)
*
|
2000-06-28 |
2003-06-24 |
Bristol Myers Squibb Co |
Selective androgen receptor modulators and methods for their identification
|
US20040077605A1
(en)
|
2001-06-20 |
2004-04-22 |
Salvati Mark E. |
Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
|
US7001911B2
(en)
*
|
2000-06-28 |
2006-02-21 |
Bristol-Myers Squibb Company |
Fused cyclic modulators of nuclear hormone receptor function
|
EP1854798A3
(en)
|
2000-09-19 |
2007-11-28 |
Bristol-Myers Squibb Company |
Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
|
US6953679B2
(en)
|
2000-09-19 |
2005-10-11 |
Bristol-Myers Squibb Company |
Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
|
US20040087548A1
(en)
|
2001-02-27 |
2004-05-06 |
Salvati Mark E. |
Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
|
US7015253B2
(en)
*
|
2001-07-10 |
2006-03-21 |
American Medical Systems, Inc. |
Regimen for treating prostate tissue and surgical kit for use in the regimen
|
ES2310622T3
(es)
*
|
2001-12-19 |
2009-01-16 |
Bristol-Myers Squibb Company |
Compuestos heterociclicos condensados y analogos de los mismos, moduladores de la funcion de los receptores nucleares de hormonas.
|
US7354933B2
(en)
*
|
2003-01-31 |
2008-04-08 |
Aventis Pharma Sa |
Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
|
FR2850652B1
(fr)
*
|
2003-01-31 |
2008-05-30 |
Aventis Pharma Sa |
Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
|
JP4709759B2
(ja)
|
2003-08-22 |
2011-06-22 |
リガンド・ファーマシューティカルズ・インコーポレイテッド |
アンドロゲン受容体モジュレーター化合物としての6−シクロアミノ−2−キノリノン誘導体
|
CA2546601A1
(en)
|
2003-11-19 |
2005-06-09 |
Metabasis Therapeutics, Inc. |
Novel phosphorus-containing thyromimetics
|
NZ548209A
(en)
*
|
2003-12-19 |
2009-07-31 |
Univ California |
Methods and materials for assessing prostate cancer thearapies
|
NZ550102A
(en)
*
|
2004-02-24 |
2010-10-29 |
Univ California |
Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
|
WO2005090282A1
(en)
*
|
2004-03-12 |
2005-09-29 |
Ligand Pharmaceuticals Incorporated |
Androgen receptor modulator compounds and methods
|
AU2005285035B2
(en)
*
|
2004-09-10 |
2012-03-22 |
Janssen Pharmaceutica N.V. |
Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS)
|
KR102324567B1
(ko)
|
2005-05-13 |
2021-11-09 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
디아릴히단토인 화합물
|
US7709517B2
(en)
|
2005-05-13 |
2010-05-04 |
The Regents Of The University Of California |
Diarylhydantoin compounds
|
JP5199079B2
(ja)
|
2005-06-17 |
2013-05-15 |
リガンド・ファーマシューティカルズ・インコーポレイテッド |
アンドロゲン受容体モジュレーター化合物および方法
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
FR2896503B1
(fr)
*
|
2006-01-23 |
2012-07-13 |
Aventis Pharma Sa |
Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
|
EP2656842B1
(en)
|
2006-03-27 |
2016-08-10 |
The Regents of The University of California |
Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
|
NZ596260A
(en)
|
2006-03-29 |
2013-05-31 |
Univ California |
Diarylthiohydantoin compounds
|
US8404896B2
(en)
|
2006-12-01 |
2013-03-26 |
Bristol-Myers Squibb Company |
N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
|
WO2008083407A1
(en)
|
2007-01-02 |
2008-07-10 |
Aquabeam Llc |
Minimally invasive methods and devices for the treatment of prostate diseases
|
US9232959B2
(en)
|
2007-01-02 |
2016-01-12 |
Aquabeam, Llc |
Multi fluid tissue resection methods and devices
|
US20080245375A1
(en)
*
|
2007-04-05 |
2008-10-09 |
Medtronic Vascular, Inc. |
Benign Prostatic Hyperplasia Treatments
|
CA2966280A1
(en)
|
2007-10-26 |
2009-04-30 |
The Regents Of The University Of California |
Diarylhydantoin compounds
|
JP5506702B2
(ja)
|
2008-03-06 |
2014-05-28 |
アクアビーム エルエルシー |
流体流れ内を伝達される光学エネルギーによる組織切除および焼灼
|
US20120046364A1
(en)
|
2009-02-10 |
2012-02-23 |
Metabasis Therapeutics, Inc. |
Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
|
US9848904B2
(en)
|
2009-03-06 |
2017-12-26 |
Procept Biorobotics Corporation |
Tissue resection and treatment with shedding pulses
|
US10524822B2
(en)
|
2009-03-06 |
2020-01-07 |
Procept Biorobotics Corporation |
Image-guided eye surgery apparatus
|
FR2944524B1
(fr)
|
2009-04-17 |
2012-11-30 |
Ipsen Pharma Sas |
Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
|
RS57309B1
(sr)
|
2010-02-16 |
2018-08-31 |
Aragon Pharmaceuticals Inc |
Modulatori androgenih receptora i njihove upotrebe
|
WO2012109387A1
(en)
|
2011-02-08 |
2012-08-16 |
Halozyme, Inc. |
Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
|
CN108606773B
(zh)
|
2012-02-29 |
2020-08-11 |
普罗赛普特生物机器人公司 |
自动化图像引导的组织切除和处理
|
MX371020B
(es)
|
2012-09-26 |
2020-01-13 |
Aragon Pharmaceuticals Inc |
Antiandrógenos para el tratamiento del cáncer de próstata resistente a la castración no metastásico.
|
JOP20200097A1
(ar)
|
2013-01-15 |
2017-06-16 |
Aragon Pharmaceuticals Inc |
معدل مستقبل أندروجين واستخداماته
|
WO2014130932A2
(en)
|
2013-02-25 |
2014-08-28 |
Novartis Ag |
Novel androgen receptor mutation
|
JP6461971B2
(ja)
|
2013-09-06 |
2019-01-30 |
プロセプト バイオロボティクス コーポレイション |
飛散パルスを用いた組織切除および処置
|
JP6651471B2
(ja)
|
2014-06-30 |
2020-02-19 |
プロセプト バイオロボティクス コーポレイション |
流体ジェット組織アブレーションおよび冷凝固(aquablation)方法および装置
|
BR112017004431B1
(pt)
|
2014-09-05 |
2022-11-01 |
Procept Biorobotics Corporation |
Aparelho para tratar um paciente
|
TWI726969B
(zh)
|
2016-01-11 |
2021-05-11 |
比利時商健生藥品公司 |
用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
|
EP3500310A1
(en)
|
2016-08-20 |
2019-06-26 |
FTF Pharma Private Limited |
Pharmaceutical composition comprising an androgen receptor inhibitor
|
CN107216290B
(zh)
*
|
2017-06-12 |
2021-03-16 |
陕西科技大学 |
一种3-丁基-5,5-二甲基海因咪唑季铵盐及其制备方法
|
KR20200070334A
(ko)
|
2017-10-16 |
2020-06-17 |
아라곤 파마슈티컬스, 인코포레이티드 |
비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
|